Member Info for TorquayFan

I rely on this 10.36 post - " . . . . every annual report and every set of interims over the last 4 years has seen timescales slide and not one target has been met. Whatever the reasons, it doesn't help to mock frustrated shareholders or to somehow suggest that PI's are being unreasonably impatient."

Inan - can't say that better myself. I'd ask you something not science based - how do you think your 10 year Investment in Immunobody is progressing?

You are as disappointed as anyone else aren't you ?

Just one post today M8. It's no you good 'Lording it' about the science - we are INVESTORS as you are too. So no point in berating Investors for a Cheer Up !

SCLP is an Investment that Management has to manage the science to achieve it's worth. That's not happening atm - whatever the potential. So calm down - it's obvious that you are frustrated too about the lack of progress or you wouldn't post as you do.

I'm sure the Rabbit WILL appear - soon hopefully. Meantime I'm guessing that Prof. Lindy is desolate at her 10 years ++ of work on Immunobody - on the rocks.

Maybe you can 'string a sentence' one day, that somebody else can identify with.

BTW lots more where that came from !! Patronising stuff from you M8

. . as ONW says, we are waiting for one to come out of the hat !

Ray's 18.41 - yes Modi 1 and AvidiMab potential are exciting but I'm not sure about the BioNTech link, which might be in another Scancell drift - BNTX certainly have many irons in the fire.

After 10 + years of pioneering slog on Immunobody, Prof. Lindy must be feeling desolate at the stalled SCIB1 Combo progress. Unfortunately, we don't even know if an IND application has been submitted yet the USA arm looks increasingly to be the only hope for Immunobody atm. News of SCIB2 from CRUK would be nice.

Here's to a blue day coming !

You can't explain because somehow, you have had my perfectly moderate message removed from the BB - an absolutely shocking manipulation. You were way off target in complaining to Bermuda who has dug you out of many silly comments lately.

I see other pertinent comments from Crackin are still there ?

This is a disgrace . . .

It's quite simple - apologise to Bermuda and . . .

Perhaps you can explain ?
"A shame none of those qualities were displayed by TF and . . . "
TCOY

From Scancell just CH listed as attending and from Vulpes, Senior VP and the MD.
Let's hope Vulpes don't find any other 'hot prospects' LOL . . .

Keynote Speakers but no programme ? I imagine it's a walkthrough format with 1 to 1 Discussions here and there. Good Luck Cliff Holloway !

Science Dept - any clues in here ?
https://www.globenewswire.com/news-release/2019/11/14/1947119/0/en/BioNTech-SE-Provides-Update-on-Corporate-Progress-and-Third-Quarter-2019-Financial-Results.html

BioNTech - some nice music here to keep you going until 14.00 CET.
Would be fun if Scancell get ANY mention at all and I'm not holding my breath.
Hope it goes well for them. Seems easy to register . .

https://investors.biontech.de/events/event-details/q3-2019-webcast

C7 08.14 - "And rather good news from CH yesterday in regards to Keith Flaherty leading the U.S. arm of the SCIB 1 Combo Trial IF we ever do get the IND through. Yes that bit of news boosted my confidence again in SCIB 1".

You do sound quite 'keen' there C7 . . . . Good on yer !

Bermuda - I don't think myself there's much comfort in 'involved' as 'not much to be involved in at the moment. Let's see what happens if/when we get an IND approval. Thanks all.

Hello The Wednesday - is that inspired by Sheffield Wednesday ?

Re. SCIB1 Combo USA arm - we don't know if the IND application has been made yet and indeed the BoD said they would not be advising us of 'application' but would be advising us if/when IND granted of course.

CH implies KF is still interested in Immunobody but if/when we get the IND, I'd guess the role he takes will be determined by his commitments at that time.

Never mind - thanks C7

Maybe Botski, maybe Ray ? Who knows ?
Perhaps when the time comes there might be 6 'featured' in I O (E) ?
Better than a few 'Posters' in a 1000 IMO. It's good - more please . . .

Crumbs thanks for that link 18.44 and as you found, Scancell's is 'the ONLY featured presentation' ! (ATM anyway). I'd guess Scancell can't choose that 'status' so the good news is - someone, somewhere else loves us ! Oh Joy !

IMO your words are worth repeating : "How has scancell not got a commercial deal yet with one of the big 'surrounding' players considering the competitiveness of this emerging market and the potential of scancells pipeline (33 targets for just the first 2 moditopes!).... still baffling".

Thanks Ray and Inan too . . . .

8 degrees - did you miss the 3 off ? Phew !

Thanks for that and indeed, 'you never know' - did you see the webcast details ? ATB

That's a bit hard on me K. Quote - "I'm not holding my breath . . . . but you never know".
And of course - 'you never know' says it fairly enough - like 'ynk' but you might win the lottery.

Now here's a challenge to Berm or some other worthy - "To participate in the conference call, please dial the following numbers five minutes prior to the start of the call and provide the Conference ID: 8453733.
United States international: +1 631 510 7495
United States domestic (toll-free): +1 866 966 1396
Germany: +49 692 443 7351"

Nice blue day to you . . .

I wonder if there'll be any comment on the cooperation with Scancell in this coming update - I'm not holding my breath but you never know :-

"BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, will announce on Thursday, November 14th, 2019 its financial results for the third quarter ended September 30, 2019. BioNTech will also host a conference call and webcast on the same day at 08:00 a.m. ET (2:00 p.m. CET) . . . "

http://www.globenewswire.com/news-release/2019/11/07/1942898/0/en/BioNTech-to-Report-Third-Quarter-2019-Financial-Results-and-Operational-Progress-on-November-14-2019.html

I know the analogy - 'shotguns vs snipers', but am not sure how it applies. IMHO Mable is not right even though she has an incisive view, BUT, perhaps CI and CI Combo are mopping up the potential Folks for trials atm and the result is the same as Mabels Pharma elbow out. A tubload of PR, appropriate or not, in recent years, would have moved the markers but, these are very sick Folks and who wants that belt in the arm every 3 weeks for 2 years ? When CI and CI Combo is becoming known as an answer . . . . ?

Just MO but Scancell need to make sure that Modi 1 does not go the same way. Let's hope something commercial comes out of AvidiMabs or Glycans or BioNTech to break this tunnel.

GLA

Crumbs thanks for your 08.17 reply Saturday and 11.12 too. I've not been posting due to severe 'Boris Stress Syndrome' but I'm better now.

Ivy I absolutely agree 100% with your 13.08 statement "Good to see more realistic posting" - spot on. IMO it's not possible to object sensibly to that statement in any way. However, it is still MO that the science WILL see us through (fingers crossed) (one day) but meantime regarding, "our dreams can make us fly", I am reliably informed that was in fact a 'typo' from the intended "our dreams can make us cry" . . . . (a wink for C7).

Bobbust 3.6 million - amazing holding and Good Luck - I'm guessing many here have around 1 million but WOW !

Crumbs your Sun 19.52 and 20.02 excellent again - just the facts and the hopes.

Bermuda's wise words Sun 15.57 - " I agree that just blaming the BOD is easy . . . . . . On the other hand the 'BOD can do no wrong and let's blame everyone else' mantra is just as easy and just as dangerous. Sometimes, it's not a question of blame so much as just understanding the issues."

How true - but it'll be hard to convince some in the other place ! GLA

We've seen 'to be' top seller Keytruda $22bn sales in 2025 and in this report, the 4th best seller is predicted as Opdivo $12bn. Big big bucks . . .

https://pharmaphorum.com/views-analysis-sales-marketing/the-best-selling-drugs-of-the-next-5-years/? Makes me worry about Mabel's theory again, (TUE 07.07)

"Just for fun - I saw Mabel's posts and the discussion last week. Mabel years ago was wondering if Big Pharma would undermine Immunobody's progress. Well we don't know quite what happened with the FDA delays but in the UK, maybe Mabel is right but indirectly - Pharma seem to be hoovering up the Patients on CI and CI Combo trials and we're not (atm)."

BIG bucks involved here - come on Scancell !

With apologies Ray, here's your post of 19th October which is worth a rerun in these disappointing days. One rider to it - can BoD run these events to expected timetables ?

Ray P - ". . . . . . . . The good thing is that many other projects are happening simultaneously and making progress :-

1 the modi1 trial is scheduled to start H1 2020. It too is likely to be delayed IMO
2 the Scib2 trial will start at some point at no expense to SCLP
3 Modi2 is being progressed with targets identified
4 the BionTech collaboration is ongoing
5 Avidimab is being assessed by a pharma
6 Likewise the glycans Mabs
7 A new Mab has been identified to stimulate certain types of memory TCells
8 software to analyse proteins to identify likely epitopes is being utilised
9 Modi3 looks to be a possibility

All of this from 1 tiny Biotech, and there are other projects taking place outeide SCLP either based on SCLP science or being sponsored by SCLP."

Time will tell as they say . . . . GLA